Physician profile
Craig E Christensen
NPI 1538250162
$853.46
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $176 · 2021: $294 · 2022: $190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $228.27 | 2019-2021 | |
| Amgen INC. | $135.41 | 2019-2022 | |
| Allergan, INC. | $96.31 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $90.73 | 2021-2022 | |
| Abbvie INC. | $86.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $62.12 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $57.93 | 2019 | |
| Gilead Sciences, INC. | $31.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $23.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.33 | 2021 | |
| Redhill Biopharma INC. | $19.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.